Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
reports
Citius Pharmaceuticals (CTXR) Stock Price & Analysis
1,124 Followers
CTXR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.77 - $2.01
Previous Close$1.39
Volume1.02M
Average Volume (3M)759.15K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-6.0
Beta1.08
Next EarningsFeb 15, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$4.00
EPS (TTM)-0.23
Shares Outstanding146,211,130
R-Squared0.05
Standard Deviation0.28
10 Day Avg. Volume1,449,382
30 Day Avg. Volume759,147
Price to Book (P/B)6.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-8.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Alpha-0.00060
Number of Analyst Covering1
Citius Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTXR FAQ
What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.77 and its highest was $2.01 in the past 12 months.
What is Citius Pharmaceuticals’s market cap?
Currently, no data Available
When is Citius Pharmaceuticals’s upcoming earnings report date?
Citius Pharmaceuticals’s upcoming earnings report date is Feb 15, 2023 which is in 13 days.
How were Citius Pharmaceuticals’s earnings last quarter?
Citius Pharmaceuticals released its earnings results on Dec 22, 2022. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Citius Pharmaceuticals overvalued?
According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued.
Does Citius Pharmaceuticals pay dividends?
Citius Pharmaceuticals does not currently pay dividends.
What is Citius Pharmaceuticals’s EPS estimate?
Citius Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Citius Pharmaceuticals have?
Citius Pharmaceuticals has 146,211,140 shares outstanding.
What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
Citius Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -17.647%.
Which hedge fund is a major shareholder of Citius Pharmaceuticals?
Among the largest hedge funds holding Citius Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Citius Pharmaceuticals’s shares valued at 27K.
---
Citius Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00
$4.00
Blogger Sentiment
Bullish
CTXR Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.83%
12-Months-Change
Fundamentals
Return on Equity
-28.63%
Trailing 12-Months
Asset Growth
-19.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
---
---